New drug RBS2418 aims to rev up immune system against tough colorectal cancer

NCT ID NCT06824064

Recruiting now Disease control Sponsor: Riboscience, LLC. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2a trial tests an experimental drug called RBS2418 in 150 adults with advanced, metastatic colorectal cancer that has worsened despite standard treatments. The drug is designed to help the immune system recognize and attack cancer cells. Participants will receive either RBS2418 or a placebo, alongside best supportive care, to see if the drug can slow tumor growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RBS2418
What this could lead to: If it works, this could offer a new treatment option for people with advanced colorectal cancer who have run out of standard therapies.
What could go wrong: This is an early Phase 2a trial with only 150 participants, so results may not confirm benefit. The drug may not slow tumor growth or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED COLORECTAL CANCER METASTATIC COLORECTAL CANCER

Contacts and locations

Locations

Christiana Care
RECRUITING

Newark, Delaware, 19718, United States
Community Clinical Trials
RECRUITING

Kingwood, Texas, 77339, United States
Pan Oncology
RECRUITING

San Juan, 00935, Puerto Rico
Tam Anh TP. Ho Chi Minh General Hospital
RECRUITING

Ho Chi Minh City, Ho Chi Minh City, 70000, Vietnam
Tam Anh, Ha Noi General Hospital
RECRUITING

Hà Nội, 10000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.